WIL Research Acquires Midwest BioResearch
Contract research organization (CRO) WIL Research Laboratories and its parent company WIL Research Holding Company have acquired Midwest BioResearch, a company that provides drug disposition and toxicology services to drug developers. Neither company provided financial details of the deal.
Midwest BioResearch president and founder Michael Schlosser, Ph.D., will continue to lead Midwest BioResearch’s Skokie, Ill., office under the management of WIL Research vice president and chief scientific officer Christopher Chengelis, Ph.D.
WIL Research, an Ashland, Ohio-based CRO specializing in toxicology services, hopes to benefit from Midwest BioResearch’s expertise in immunoanalytical and bioassay techniques and small molecule bioanalysis.
“Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities,” Chengelis said in a company statement. “We also benefit from a world-class staff with significant pharmaceutical and biotechnology industry experience and the addition of a program services consulting group.”